Aptevo Therapeutics Inc (APVO)

May 29, 2025

Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decrease in Short Interest - Defense World

May 29, 2025

May 25, 2025

Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | AP - GuruFocus

May 25, 2025

May 23, 2025

Aptevo Therapeutics (APVO) Trading Suspended as News Awaits | APVO Stock News - GuruFocus

May 23, 2025

May 23, 2025

Aptevo Therapeutics Approves 1-for-20 Reverse Stock Split - TipRanks

May 23, 2025

May 22, 2025

Aptevo Therapeutics Announces Reverse Stock Split - TipRanks

May 22, 2025

May 22, 2025

Aptevo Therapeutics to Implement 1-for-20 Reverse Stock Split - marketscreener.com

May 22, 2025

May 22, 2025

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as pa - GuruFocus

May 22, 2025

May 22, 2025

Aptevo Therapeutics (APVO) Announces 1-for-20 Reverse Stock Split | APVO Stock News - GuruFocus

May 22, 2025

May 22, 2025

Aptevo Therapeutics enacts reverse stock split to maintain Nasdaq compliance - Investing.com

May 22, 2025

May 22, 2025

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan - ACCESS Newswire

May 22, 2025

May 22, 2025

Aptevo's Dramatic 1:20 Reverse Split Cuts Shares from 13.5M to 0.7M in Nasdaq Compliance Push - Stock Titan

May 22, 2025

May 18, 2025

StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World

May 18, 2025

May 16, 2025

Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

May 15, 2025

Aptevo reports high remission in AML patients with new drug By Investing.com - Investing.com South Africa

May 15, 2025

May 15, 2025

APVO: Promising Trial Results Propel AML Treatment Innovations | - GuruFocus

May 15, 2025

May 15, 2025

APVO: Promising Trial Results Propel AML Treatment Innovations | APVO Stock News - GuruFocus

May 15, 2025

May 15, 2025

Aptevo reports high remission in AML patients with new drug - Investing.com Australia

May 15, 2025

May 15, 2025

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig | APVO Stock News - GuruFocus

May 15, 2025

May 15, 2025

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig - ACCESS Newswire

May 15, 2025

May 14, 2025

Breakthrough: New AML Drug Shows 90% Remission Rate With Zero Cytokine Release Syndrome - Stock Titan

May 14, 2025

May 12, 2025

Aptevo Therapeutics (APVO) Expected to Announce Earnings on Wednesday - Defense World

May 12, 2025

May 10, 2025

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World

May 10, 2025

May 08, 2025

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - ACCESS Newswire

May 08, 2025

May 08, 2025

Aptevo Therapeutics Provides Program Update for Bispecific APVO7 - GuruFocus

May 08, 2025

May 08, 2025

Aptevo Therapeutics Says In Preclinical Studies APVO711 Demonstrates Dual Anti-Cancer Functionality - marketscreener.com

May 08, 2025

May 08, 2025

Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy wit - GuruFocus

May 08, 2025

May 08, 2025

Aptevo Therapeutics (APVO) Advances Innovative Immunotherapy with APVO711 Update | APVO Stock News - GuruFocus

May 08, 2025

May 08, 2025

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation | APVO Stock News - GuruFocus

May 08, 2025

May 08, 2025

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation - ACCESS Newswire

May 08, 2025

May 01, 2025

Aptevo Therapeutics announces common stock offering - Investing.com Australia

May 01, 2025

Apr 30, 2025

APVO’s latest rating updates from top analysts. - knoxdaily.com

Apr 30, 2025

Apr 30, 2025

Strategic Moves Drive Stock Gains For OSR, Lianhe Sowell, And Aptevo - Finimize

Apr 30, 2025

Apr 29, 2025

Aptevo Therapeutics announces common stock offering By Investing.com - Investing.com Canada

Apr 29, 2025

Apr 29, 2025

Closing Bell Recap: Aptevo Therapeutics Inc (APVO) Ends at 0.61, Reflecting a -9.31 Downturn - DWinneX

Apr 29, 2025

Apr 29, 2025

Aptevo Therapeutics announces at-the-market offering - Investing.com Australia

Apr 29, 2025

Apr 28, 2025

APVO stock plunges to 52-week low, touches $0.59 - Investing.com

Apr 28, 2025

Apr 28, 2025

APVO stock plunges to 52-week low, touches $0.59 By Investing.com - Investing.com UK

Apr 28, 2025

Apr 28, 2025

Aptevo Therapeutics announces at-the-market offering By Investing.com - Investing.com India

Apr 28, 2025

Apr 28, 2025

SEC Form 424B4 filed by Aptevo Therapeutics Inc. - Quantisnow

Apr 28, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 26, 2025

Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering - ACCESS Newswire

Apr 26, 2025

Apr 25, 2025

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - ACCESS Newswire

Apr 25, 2025

Apr 25, 2025

Applied Materials Q2 Earnings: Tech Giant's Financial Results Coming May 15 - Stock Titan

Apr 25, 2025

Apr 24, 2025

A look into Aptevo Therapeutics Inc (APVO)’s deeper side - Sete News

Apr 24, 2025

Apr 23, 2025

Aptevo Therapeutics Inc’s latest rating changes from various analysts - knoxdaily.com

Apr 23, 2025

Apr 23, 2025

Evogene (EVGN) Sees Dramatic Surge in Investor Interest Amid Strategic Moves | APVO Stock News - GuruFocus

Apr 23, 2025

Apr 23, 2025

Market Momentum: Aptevo Therapeutics Inc (APVO) Registers a 9.08 Increase, Closing at 0.69 - DWinneX

Apr 23, 2025